Sentences with phrase «diabetes therapy company»

Not exact matches

The U.S. attorney's office in Indianapolis had alleged that Guoqing Cao and Shuyu Li, both naturalized U.S. citizens and senior biologists at Eli Lilly, passed research on tailored therapies for cancer and drugs to treat diabetes, obesity, and other metabolic disorders to Jiangsu Hengrui Medicine, a company in Lianyungang, China.

Raydiance's technology has attracted the attention of the U.S. Food and Drug Administration (FDA), which in July 2007 signed the company to a two - year cooperative research and development agreement that has allowed the FDA's Center for Devices and Radiological Health (CDRH) to evaluate the use, safety and effectiveness of Raydiance's USP laser system in a number of areas, including the ablation of corneal tissues in refractive surgery and corneal repair; the administration of light therapy for treating cancer, cardiovascular disease and diabetes; and the removal of plaque on teeth without damaging the enamel.

«Given the growing epidemic of obesity, diabetes, and NAFLD, this study brings to the attention of policymakers, providers, pharmaceutical companies, payers, and patients the critical importance of understanding NAFLD and establishing a policy for prevention, early detection, and effective therapy,» said Dr. Younossi.

Zucara Therapeutics, a spin - off company by The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI), is developing the first drug therapy to prevent hypoglycemia in people with diabetes.

San Diego, California, October 10, 2013 — ViaCyte, Inc. announced today that an update on the Company's progress toward a transformative stem cell - derived cell therapy for the treatment of type 1 diabetes will be presented at the 3rd Annual Regen Med Partnering Forum, part of the 2013 Stem Cell Meeting on the Mesa to be held October 14 - 16 in La Jolla, California.

SAN DIEGO and BETHESDA, MD, March 3, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Eugene Brandon, Director of Strategic Relations and Project Management, at the JDRF TypeOneNation Summit.

SAN DIEGO, April 20, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced four presentations at upcoming healthcare events.

Making this even more historic, ViaCyte recently acquired the assets of BetaLogics, a company that for more than a decade has also been working toward a stem cell - derived therapy for diabetes.

The company is the first to advance an encapsulated islet cell replacement therapy for type 1 diabetes into clinical trials.

ViaCyte, a private company that has emerged as a leader in the field of regenerative medicine, is currently focused on developing a novel cell therapy for the treatment of diabetes.

SAN DIEGO, September 9, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced participation on a panel at the 2016 BioPharm ™ America — 9th Annual International Partnering Conference.

SAN DIEGO, March 17, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Paul Laikind, President and CEO, at the third annual Regen Med Investor Day co-hosted by the Alliance for Regenerative Medicine (ARM) and top financial firm Piper Jaffray.

San Diego, January 8, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Company's Phase 1/2 clinical trial of its VC - 01TM product cancompany with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Company's Phase 1/2 clinical trial of its VC - 01TM product canCompany's Phase 1/2 clinical trial of its VC - 01TM product candidate.

San Diego, California, October 6, 2014 — ViaCyte, Inc., a privately - held regenerative medicine company developing a stem cell - derived islet replacement therapy for the treatment of diabetes, called VC - 01 ™, will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follows:

ViaCyte is a privately - held, clinical - stage regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.

ViaCyte is a preclinical cell therapy company focused on diabetes.

SAN DIEGO, March 1, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced presentations at the JDRF TypeOneNation Summit meetings being held in Washington DC and Los Angeles.

«It has been rewarding to be a part of a company that has pioneered the development of stem cell therapy, including the development of technologies that hold promise for the treatment of diabetes,» said Lewis.

The Company's pluripotent stem cell - derived islet cell replacement therapy, the PEC - Direct ™ product candidate, has the potential to be a breakthrough treatment for high - risk type 1 diabetes.

San Diego, August 1, 2017 — ViaCyte, Inc., a privately - held, leading regenerative medicine company, announced today that the first patients have been implanted with the PEC - Direct ™ product candidate, a novel islet cell replacement therapy in development as a functional cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.

Novocell, Inc. is a stem cell engineering company with research operations in San Diego, California and Athens, Georgia, dedicated to creating, delivering and commercializing cell and drug therapies for diabetes and other chronic diseases.

San Diego, CA (March 31, 2009)-- Novocell, Inc., a stem cell engineering company, today announced that it has received U.S. Patent 7,510,876 with claims covering human definitive endoderm cells, an essential cell for generating not only pancreatic type cells, which Novocell is developing for use as a cell therapy for diabetes, but also other endoderm lineage - derived tissues and organs such as lungs, intestine, liver, thymus and thyroid.

SAN DIEGO, June 22, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced two presentations at ISSCR 2016 Annual Meeting.

ViaCyte is a privately held, clinical - stage regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.

Stem Cell Therapy company presents a collection of stem cell - based therapy summaries for multiple diseases such as diabetes, liver disease, lung disease, osteoarthritis anTherapy company presents a collection of stem cell - based therapy summaries for multiple diseases such as diabetes, liver disease, lung disease, osteoarthritis antherapy summaries for multiple diseases such as diabetes, liver disease, lung disease, osteoarthritis and more.

As the first company to advance a cell replacement therapy for type 1 diabetes into the clinic, ViaCyte is committed to developing a functional cure for all type 1 diabetes patients.

The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group and Diabetes Group.